Abstract
OBJECTIVE: To examine the effect of dietary restraint during and following pegylated recombinant leptin (PEG-OB protein) treatment in overweight men.
DESIGN: A randomized double-blind placebo-controlled trial in 24 overweight men (BMI: 28.8±0.3 kg/m2; age: 34.8±0.9 y). PEG-OB protein (80 mg) or placebo was administered subcutaneously weekly for 6 weeks, combined with a 2.1 MJ/day energy restriction program. Dietary restraint was determined by the Three-Factor Eating Questionnaire before and after treatment, and after 8 weeks follow-up.
RESULTS: During treatment dietary restraint increased, and general hunger, resting energy expenditure and respiratory quotient decreased similarly in the PEG-OB and the placebo group. With PEG-OB treatment, additional weight loss (P<0.03) was observed. During 8 weeks follow-up, body weight increase was larger in the PEG-OB group compared to placebo (P<0.05), and body weight regain was faster. Body weight regain was inversely correlated with the increase in cognitive dietary restraint during treatment (PEG-OB group: r2=0.49, P<0.02; placebo group: r2=0.60, P=0.01).
CONCLUSION: Although treatment with PEG-OB protein led to a greater body weight loss relative to placebo, weight maintenance thereafter was mainly supported by dietary restraint, which was more effective in the placebo-treated group, resulting in a slower regain of body weight.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Seidell JC . Dietary fat and obesity: an epidemiologic perspective. Am J Clin Nutr 1998; 67: 546S–550S.
National Institutes of Health Consensus Developments Panel on the Health Implications of Obesity. Health implications of obesity. Ann Intern Med 1985; 103: 1073–1077.
Lew E . Mortality and weight: insured lives and the American Cancer Society. Ann Intern Med 1985; 103: 1024–1029.
Hubert H, Feinleid M, McNamara P, Casrelli WP . Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 986–977.
Donahue R, Abbott RD, Bloom E, Reed DH, Yano K . Central obesity and coronary heart disease in men. Lancet 1987; 1: 821–824.
Pasman WJ, Rössner S, Westerterp-Plantenga MS, Saris WHM . Body weight changes after treatment of obesity or pregnancy. In: Westerterp-Plantenga MS, Steffens A, Tremblay A (eds). Regulation of food intake. EDRA: Milan; 1999.
Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P . A comparison of sibutramine and dexfenfluramine in the treatment of obesity. Obes Res 1998; 6: 285–291.
Muls E, Kempen K, Vansant G, Saris WHM . Is weight cycling detrimental to health? A review of the literature in humans. Int J Obes Relat Metab Disord 1995; 19(Suppl 3): S46–S50.
Sjöstrom L, Rissanen A, Andersen T, Bolorin M, Golay A, Koppeschaar HP . Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167–172.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM . Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425–432.
Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P . The OB protein (leptin) pathway: a link between adipose tissue mass and central neural networks. Horm Metab Res 1996; 28: 619–632.
Campfield LA, Smith FJ, Burn P . OB protein: a hormonal controller of central neural network mediating behavioral, metabolic and neuro endocrine responses. Endocrinol Metab 1997; 4: 81–102.
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohanisesiian JP, Maarco CC, McKee LY, Bauer TL . Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Eng J Med 1996; 334: 292–295.
Pasman WJ, Westerterp-Plantenga MS, Saris WHM . The effect of exercise training on leptin levels in obese males. Am J Physiol 1998; 274: E280–E286.
Heymsfield SB, Greenberg AS, Fujioka K, Didelimon RM, Kushner R, Hunt T, Lubina JA, Patanee J, Self B, Hunt P, McCahish H . Recombinant leptin for weight loss in obese and lean adults. A randomized, controlled dose-escalation trial. JAMA 1999; 282: 1568–1575.
Farooqi LS, Jebb S, Langmack G . Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Eng J Med 1999; 341: 879–884.
Westerterp-Plantenga MS, Saris WHM, Hukshorn CJ, Campfield LA . Effects of weekly administration of pegylated recombinant human OB-protein on appetite profile and energy metabolism in obese men. Am J Clin Nutr 2001; 74: 426–434.
Stunkard AJ, Messick S . The Three Factor Eating Questionnaire to measure dietary restraint, disinhibition and hunger. Psychol Res 1985; 29:71–83.
Pasman WJ, Saris WHM, Westerterp-Plantenga MS . Predictors of weight maintenance. Obes Res 1999; 7: 43–50.
Westerterp-Plantenga MS, Kempen KP, Saris WHM . Determinants of weight maintenance in women after diet-induced weight reduction. Int J Obes Relat Metab Disord 1998; 22: 1–6.
Pekkarinen T, Takala I, Mustajoki P . Two year maintenance of weight loss after a VLCD and behavioral therapy for obesity: correlation to the scores of questionnaires measuring eating behavior. Int J Obes Relat Metab Disord 1996; 20: 332–337.
Clark MM, Marcus BH, Pera V, Niaura RS . Changes in eating inventory scores following obesity treatment. Int J Eat Disord 1994; 15:401–405.
Lejeune MPGM, Van Aggel DCP, Van Baak MA, Westerterp-Plantenga MS . Dietary restraint during weight maintenance with or without exercise training, in men. Eur J Clin Nutr (in press).
d'Amore A, Massignan C, Montera P, Moles A, De Lorenzo A, Scucchi S . Relationship between dietary restraint, binge eating, and leptin in obese women. Int J Obes Relat Metab Disord 2001; 25: 373–377.
Von Prittwitz S, Blum WF, Ziegler A, Scharmann S, Remschmidt H, Hebebrand J . Restrained eating, measured with the TFEQ is associated with low leptin levels in underweight females. Mol Psychiatry 1997; 2: 420–422.
Westerterp-Plantenga MS, Rolland V, Wilson SA, Westerterp KR . Satiety related to 24 h diet-induced thermogenesis during high protein/carbohydrate vs high fat diets measured in a respiration chamber. Eur J Clin Nutr 1999; 53: 495–502.
Nucci ML, Shor R, Abuchoweski A . The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Delivery Rev 1991; 6: 133–151.
Fuertges F, Abuchoweski A . The clinical efficacy of poly(ethylene glycol)-modified proteins. J Controlled Rel 1990; 11: 139–148.
Campfield LA, Devos R, Guisez Y . Pegylated obese (OB) protein compositions. US Patent Number 6,025,324, 2/15/2000.
Bailon P, Campfield LA, Devos R . Pegylated obese (OB) protein compositions. US Patent Number 6,025,325, 2/15/2000.
Westerterp KR, Wouters L, Van Marken Lichtenbelt WD . The Maastricht protocol for the measurement of body composition and energy expenditure with labeled water. Obes Res 1995; 3(Suppl 1): 49–57.
Siri WE . The gross composition of the body. Adv Biol Med Physiol 1956; 4: 239–280.
Hukshorn CJ, Saris WHM, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA . Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000; 85: 4003–4009.
Schoffelen PFM, Westerterp KR, Saris WHM, Ten Hoor F . A dual respiration chamber with automated calibration. J Appl Physiol 1997; 83: 2064–2072.
Weir JBDV . New methods for calculating metabolic rate with special references to protein metabolism. J Physiol 1949; 109: 1–9.
Hukshorn CJ, Westerterp-Plantenga MS, Saris WHM . Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severly energy-restricted, overweight men. Am J Clin Nutr 2003; 77: 771–776.
Kahler A, Geary N, Eckel LA, Campfield LA, Smith FJ, Langhans W . Chronic administration of OB protein decreases food intake by selectively reducing meal size in male rat. Am J Physiol 1998; 275: R180–R185.
Eckel LA, Langhans W, Kahler A, Campfield LA, Smith FJ, Geary N . Chronic administration of OB protein decreases food intake by selectively reducing meal size in female rat. Am J Physiol 1998; 275: R186–R193.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lejeune, M., Hukshorn, C., Saris, W. et al. Effect of dietary restraint during and following pegylated recombinant leptin (PEG-OB) treatment of overweight men. Int J Obes 27, 1494–1499 (2003). https://doi.org/10.1038/sj.ijo.0802431
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0802431
Keywords
This article is cited by
-
Differential mechanisms affecting weight loss and weight loss maintenance
Nature Metabolism (2023)
-
Anti-obesity drug discovery: advances and challenges
Nature Reviews Drug Discovery (2022)
-
Leptin alters energy intake and fat mass but not energy expenditure in lean subjects
Nature Communications (2020)
-
Effect of Orlistat on Eating Behavior Among Participants in a 3‐year Weight Maintenance Trial
Obesity (2008)
-
Drug Insight: the role of leptin in human physiology and pathophysiology—emerging clinical applications
Nature Clinical Practice Endocrinology & Metabolism (2006)